Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a potentially unlocking a $3 billion market in the U.S. Kura's pipeline also ...

mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor. The primary endpoint was met ...

The mutation types being explored are AML patients with KMT2Ar and mNPM1 types. It is said that about 30% of AML patients have the NPM1 mutant subtype and then about 10% of AML and Acute ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...

As a Japan based global specialty pharmaceutical company, Kyowa Kirin aims to create treatments with life-changing value that bring smiles to people living with disease. The company will leverage its ...

Kura Oncology & Kyowa Kirin ink global strategic collaboration to develop and commercialize ziftomenib in acute leukaemias: San Diego Friday, November 22, 2024, 14:00 Hrs [IST] Ku ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...